Skip to main content
. 2009 Jun 30;5(2):53–64. doi: 10.3988/jcn.2009.5.2.53

Table 1.

Clinical and laboratory features in MuSK-MG, DSN-MG, and AChR-MG Generalized MG

graphic file with name jcn-5-53-i001.jpg

*Good or excellent responses, Compared with DSN-MG, Follow-up period: ≥3 yr. Mean Follow-up period: 10.6±8.0 yr in MuSK-MG, 8.5±5.5 yr in DSN-MG. 9.8±5.9 yr in AChR-MG. CSR: complete stable remission, IMS: immunosuppressive therapy MM: minimal manifestation, PE: plasma exchange, PR: pharmacological resmission.